HIV drug access extended for kids in ongoing safety study
NCT ID NCT02494986
First seen Nov 01, 2025 · Last updated May 14, 2026 · Updated 27 times
Summary
This study offers continued access to the HIV medication rilpivirine for children and teens who previously took it in a clinical trial and were still benefiting. About 48 participants will be monitored for long-term safety, including side effects and serious events. The goal is to keep the virus under control while checking for any problems over time.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Study site
Porto, Portugal
-
Study site
Bloemfontein, South Africa
-
Study site
Dundee, South Africa
-
Study site
Esplugues de Llobregat, Spain
-
Study site
Bangkok, Thailand
-
Study site
Nonthaburi, Thailand
-
Study site
Entebbe, Uganda
-
Study site
Kampala, Uganda
Conditions
Explore the condition pages connected to this study.